BIOLASE Comments on Oracle Partners L.P. Press Release

BIOLASE Comments on Oracle Partners L.P. Press Release 
IRVINE, CA -- (Marketwired) -- 03/13/14 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, including the Company's proprietary WaterLase(R), and a
pioneer in laser surgery in other medical specialties, as well as a
distributor of digital radiography, intra oral scanners, and
chair-side milling machines and 3-D printers for dentistry, today
issued a statement in response to a press release issued by Oracle
Partners L.P. ("Oracle") announcing its nomination of four director
candidates to stand for election to the BIOLASE(R) Board of Directors
at the Company's 2014 Annual Meeting of Stockholders. BIOLASE
shareholders are not required to take any action at this time. 
BIOLASE issued the following statement:  
BIOLASE welcomes open communications with its shareholders and values
constructive ideas that advance the Board's goal of enhancing value
for all shareholders. BIOLASE is executing a robust strategic plan to
build a platform on which we can leverage our Total Technology
Solution(TM) to achieve long-term growth and deliver value to BIOLASE
shareholders. The Board and management team will continue to take
actions that we believe enable us to achieve this objective. 
On March 11, 2014, Oracle, which reports that it is a 16% shareholder
of the Company, filed a lawsuit in the Chancery Court of Delaware
seeking a Court determination of the composition of the Board and a
temporary restraining order that would preclude the Board from taking
any action without the approval of four purported directors whose
directorships Oracle claims to be undisputed. The Company will
respond to Oracle's claims in the Chancery Court. Furthermore, the
Nominating and Corporate Governance Committee will consider Oracle's
other nominees in due course. The date of the Company's 2014 Annual
Meeting of Stockholders has not yet been announced. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment, CAD/CAM intraoral scanners, and in-office
milling machines and 3D printers; products that are focused on
technologies that advanc
e the practice of dentistry and medicine. The
Company's proprietary laser products incorporate approximately 300
patented and patent-pending technologies designed to provide
biologically clinically superior performance with less pain and
faster recovery times. Its innovative products provide cutting-edge
technology at competitive prices to deliver the best results for
dentists and patients. BIOLASE's principal products are revolutionary
dental laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications, and a full line
of dental imaging equipment. BIOLASE has sold more than 25,000
lasers. Other laser products under development address ophthalmology
and other medical and consumer markets. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Google+ at, Instagram at, and YouTube at  
BIOLASE(R), WaterLase(R), and Total Technology Solution(TM) are
registered trademarks or trademarks of BIOLASE, Inc. 
Forward Looking Information
 This press release may contain
forward-looking statements and information within the meaning of safe
harbor provided by the Securities Reform Act of 1995 that are based
on the current expectations and estimates by BIOLASE. These
forward-looking statements can be identified through the use of words
such as "anticipates," "expects," "intends," "plans," "believes,"
"seeks," "estimates," "may," "will," and variations of these words or
similar expressions. Forward-looking statements are based on
BIOLASE's current, preliminary expectations and are subject to risks,
uncertainties and other factors which may cause the Company's actual
results to differ materially from the statements contained herein,
and are described in the Company's reports it files with the
Securities and Exchange Commission, including its annual and
quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change,
and BIOLASE undertakes no obligation to update such statements. 
For further information, please contact:  
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Annabelle Rinehart
Press spacebar to pause and continue. Press esc to stop.